John co-founded Hatteras in 2000 after a successful career as a technology entrepreneur. Following a decade in politics and public policy, he was founder and CEO of E-Comm, Inc., a software development and services firm specializing in remote and mobile computing. After E-Comm’s acquisition by XcelleNet, Inc. (XNET), John ran the services division there until the company was acquired by Sterling Commerce (SE). Following the acquisition, John founded Hatteras with Clay Thorp.
At Hatteras, John is responsible for the firm’s investments in healthcare and life science information technology, and overall fund operations.
With his partners at Hatteras John has helped build a seed and early-stage venture capital partnership with over $800 million under management in seven funds. In that time, he has served on the boards of Synthematix, a chemistry informatics company that was acquired by Symyx Technologies (SMMX); Clinverse, a financial lifecycle management technology provider to contract research organizations and pharmaceutical companies, acquired by Bioclinica, Inc.; Bivarus, a survey-based health analytics company acquired by Press Ganey; NurseGrid, the nation’s most widely distributed nurse scheduling platform, acquired by HealthStream; Medfusion, a leading patient engagement platform, acquired by NextGen; Clinipace Worldwide, a provider of personalized clinical research solutions, acquired by dMed; and Iris Healthcare, the leading provider of comprehensive Advance Care Planning, acquired by Aledade. John currently serves on the boards of Huma.AI, Elligo Health Research, Wildflower Health, Jumo Health, and as an observer at SafeRide. He holds an A.B. from Harvard University.
Throughout his career John has been active in government and public policy at the state and federal levels. A recipient of the Lyndhurst Prize, John served on the N. C. Economic Development Board, the state’s Clean Water Management Trust Fund board of directors, the Council for Entrepreneurial Development, as a trustee of the University of North Carolina School of the Arts, and on the national advisory board of Organizing for Action. He currently serves as a longstanding board leader at SouthLight Healthcare, a non-profit provider of substance use treatment and mental health services, and on the board of the North Carolina Wildlife Federation. He is active at White Memorial Presbyterian Church and an enthusiastic member of the OnPoint House Band that plays for worship every Sunday. He has also been a member of the Americana band, Bloomsbury, for over 35 years and plays banjo in the Southern String Band.
Kenneth B. Lee, Jr. is a general partner of some of the Hatteras Ventures funds. Hatteras is a Durham (N. C.)-based early stage, life sciences focused venture capital fund. Ken is the former co-head of the International Life Sciences Practice for Ernst & Young, where he established a career over 29 years advising biotechnology and pharmaceutical companies throughout the world.
He got his start in biotech as part of the first audit team of Genentech in 1976. As co-founder and manager of the EY’s national life sciences practice from his location in the San Francisco Bay Area, he advised numerous high profile life science companies with their initial public offerings, mergers and acquisitions, and strategic financings. Among others, these firms included: Affymax, Affymetrix, Applied ImmuneSciences, Chiron, Circadian, Genentech, Heartport, Systemix, ALZA, and Collagen.
Ken has served on the Board of Directors 10 publicly held life sciences companies, including CV Therapeutics, Abgenix, Maxygen, OSI, Inspire Pharmaceuticals, and Biocryst, among others. He also served on the boards of several privately-held life sciences companies.
Ken served as Chief Financial Officer and interim Chief Executive Officer of the CEO Roundtable On Cancer, a not-for-profit organization founded by George H. W. Bush, Dr. Marty Murphy and Robert Ingram. He also served on the Boards of the UNC Health Foundation and of NCBIO.
Ken graduated with a BA from Lenoir-Rhyne College and has an MBA from the University of North Carolina at Chapel Hill.
David Jessen is a retired partner from the international accounting firm Ernst & Young. Over the course of his 35-year career, he served as Director of Tax, Carolinas’ and Southeast Region Director of Entrepreneurial Services, and Office Managing Partner. David provided tax and financial consulting services to public and private corporations in pharmaceutical, biotech, manufacturing, telecom, real estate, and other industries. His technical specialties included equity compensation, FAS 109, mergers and acquisitions, due diligence, business formation, and international tax issues.
David is currently the Executive-in-Residence at the University of North Carolina-Wilmington, Cameron School of Business, having joined its faculty in the Department of Accountancy and Business Law in August 2008.
David is a licensed CPA who received his undergraduate degree from the University of New Mexico. He also completed the Ernst & Young Executive Development Program conducted by Harvard University.
David has served on several community boards, many as treasurer, including: Wake Med Health & Hospitals, Inc., Wake Med Foundation, Inc., North Carolina Museum of Art Foundation, Food Bank of North Carolina, Council for Entrepreneurial Development, North Carolina Society to Prevent Blindness, and others.
Ann is the Executive Director of the Society for Translational Oncology (STO). Ann has served on the board of STO for over two decades working closely with other board members to identify the needs of oncology and hematology practitioners and steering STO to create and implement strategies and programs to enhance care for cancer patients and others with weakened immune systems.
Ann is also the President and CEO of AlphaMed Press. Under Ann’s leadership, AlphaMed Press founded three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines: THE ONCOLOGIST® (1996), devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care; STEM CELLS® (1983), the world's first journal devoted to this fast-paced field of research; and STEM CELLS TRANSLATIONAL MEDICINE® (2011), bridging stem cell research and clinical trials. In January 2022, these three journals were entrusted, via acquisition, to Oxford University Press (OUP).
Ann’s community and philanthropic board engagements include membership on University of North Carolina-Chapel Hill Board of Visitors and on the board of directors of Regenerative Medicine Foundation.
Marty was for two decades Founding CEO and Board Director of the non-profit CEO Roundtable on Cancer at the request of the 41st President George H.W. Bush. Marty was also Founding CEO of Project Data Sphere ®, a non-profit initiative of the CEO Roundtable devoted to cancer clinical trial data-sharing and analysis. He is Founder and current Chief Executive Officer of the non-profit Shanghai TuoXin Health Promotion Center that has expanded its purview from cancer prevention and improving cancer patient outcomes to include international Covid-19 interventions and global pandemic preparedness.
Founding Executive Editor of the 27-year-old peer-reviewed journal, THE ONCOLOGIST®, Marty is also Founding Editor of STEM CELLS®, the 40-year-old flagship journal of stem cell biology, and Co-Founder of its 11-year-old sister journal, STEM CELLS TRANSLATIONAL MEDICINE® reporting on stem cells in clinical trials. In 2021 he became Director Emeritus of the CEO Roundtable on Cancer. He co-chairs the Scientific & Strategic Advisory Council of the International COVID-19 Data Alliance of the Bill & Melinda Gates Foundation.
A former NIH principal investigator, Marty has authored more than 180 primary peer-accepted papers and 7 books, is Co-Founder and Convener of Society for Translational Oncology, member of six Scientific Advisory Boards, two corporate boards of directors, Chairman Emeritus of Conquer Cancer—ASCO Foundation, and Steering Member of Chinese Society of Clinical Oncology. He is an Emeritus Member of National Cancer Policy Forum of National Academy of Medicine (US National Academy of Sciences), board member of Center for Public Health Advisory Board of the Milken Institute, Director Emeritus of Foundation for NIH, Fellow of American Society of Clinical Oncology, and former vice chairman of C-Change. Marty is married to Ann Murphy, PhD, President and Founder of AlphaMed Press and Co-founder and Executive Director of Society for Translational Oncology. They have five adult children and ten grandchildren.
Copyright © 2022. All rights reserved.